NRF2 agonists 4-octyl-itaconate and dimethyl fumarate reduce human and bovine RSV proliferation and RSV disease in a murine model
- PMID: 40854594
- PMCID: PMC12377912
- DOI: 10.1093/immhor/vlaf036
NRF2 agonists 4-octyl-itaconate and dimethyl fumarate reduce human and bovine RSV proliferation and RSV disease in a murine model
Abstract
Human and bovine respiratory syncytial virus (RSV) are significant causes of morbidity and mortality in human and cattle populations worldwide, respectively. RSV disease is characterized by deleterious inflammatory immune responses as well as generation of radical oxygen species in the airways. Recent reports have shown antiviral and anti-inflammatory activity of NRF2 agonists and immunometabolite derivatives 4-octyl-itaconate (4-OI) and dimethyl fumarate (DMF), suggesting their potential to protect against viral-induced inflammation. Here, we evaluated whether 4-OI or DMF impact human and bovine RSV replication and its associated inflammatory response in vitro and the efficacy of these NRF2 agonists in preventing RSV disease in a murine model. We observed that 4-OI and DMF inhibited the early inflammatory response to RSV as well as reduced infectious titers in epithelial cells. Moreover, mice treated with 4-OI or DMF were partially protected against RSV-induced weight loss and airway inflammation and showed reduced viral loads and interleukin-6 levels in the lung. Overall, these results support the use of NRF2 agonists 4-OI and DMF in the prevention of RSV disease in target populations.
Keywords: large animals; lung; rodent; viral.
© The Author(s) 2025. Published by Oxford University Press on behalf of The American Association of Immunologists.
Conflict of interest statement
The authors have no financial conflicts of interest.
Figures





Similar articles
-
Polyanhydride nanoparticles encapsulating innate sensor agonists activate epithelial and airway cells and reduce Respiratory Syncytial Virus infection in mice.Acta Biomater. 2025 Jul 1;201:501-516. doi: 10.1016/j.actbio.2025.05.061. Epub 2025 May 24. Acta Biomater. 2025. PMID: 40419069
-
Elimination of gut microbiota hinders the therapeutic effect of amentoflavone on respiratory syncytial virus-induced lung inflammation injury by regulating innate immunity.Phytomedicine. 2025 Sep;145:157033. doi: 10.1016/j.phymed.2025.157033. Epub 2025 Jul 8. Phytomedicine. 2025. PMID: 40701130
-
Both chebulagic acid and punicalagin inhibit respiratory syncytial virus entry via multi-targeting glycoprotein and fusion protein.J Virol. 2024 Dec 17;98(12):e0153624. doi: 10.1128/jvi.01536-24. Epub 2024 Nov 7. J Virol. 2024. PMID: 39508604 Free PMC article.
-
Host immune response to respiratory syncytial virus infection and its contribution to protection and susceptibility in adults: a systematic literature review.Expert Rev Clin Immunol. 2025 Jun;21(6):745-760. doi: 10.1080/1744666X.2025.2494658. Epub 2025 May 2. Expert Rev Clin Immunol. 2025. PMID: 40278893 Review.
-
Role of human infection challenge studies (HICs) in drug development for respiratory syncytial virus (RSV): systematic review and meta-analysis.EBioMedicine. 2025 Jul;117:105765. doi: 10.1016/j.ebiom.2025.105765. Epub 2025 May 29. EBioMedicine. 2025. PMID: 40446400 Free PMC article.
References
-
- Sigurs N et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax. 2010;65:1045–1052. - PubMed
-
- Silvestri M, Sabatini F, Defilippi AC, Rossi GA. The wheezy infant—immunological and molecular considerations. Paediatr Respir Rev. 2004;5(Suppl A):S81–S87. - PubMed
-
- Sacco RE, McGill JL, Pillatzki AE, Palmer MV, Ackermann MR. Respiratory syncytial virus infection in cattle. Vet Pathol. 2014;51:427–436. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical